Aqsens Health develops and offers non-invasive screening tests for urinary tract cancers and lethal infectious diseases. The company’s patented Enhanced-TRF method, use of biosensors and machine learning provide unparalleled sensitivity and specificity in diagnosing diseases at their early stage. The company’s focus is on non-invasive screening of health disorders that have a major impact on individual patients and societies worldwide. Aqsens Health's current research projects and interest include urinary tract cancer, prostate cancer, oral cancer and malaria. In the future Aqsens plans to begin research on tuberculosis and cholera.